Atai Life Sciences (Nasdaq:ATAI) announced inconclusive data regarding the effects of the kratom-derived compound KUR-101 on respiration in a Phase 1 study.
The company’s stock was down about 9% in mid-day trading, trading at $2.77.
The drug candidate yielded dose-dependent analgesic effects in Part 1 of the study, which assessed the safety and efficacy of various dose levels of KUR-101 (10, 20, 40, 60 and 90 mg).
Data from Part 2 of the Phase 1 study found that a 90 mg dose of KUR-101 yielded analgesic effects in the cold-pressor test and thermal testing, but oxycodone was superior at relieving pain. In that study, KUR-101 and oxycodone had a similar effect on respiration to placebo, preventing a definitive assessment of KUR-101’s impact on respiration.
“As the data comparing the respiratory effects of KUR-101 to both oxycodone and placebo are inconclusive at this stage, additional research will be needed to further characterize the therapeutic p…